The severity of COVID-19 disease is attributed to the inflammatory condition associated with the disease and leading to increased mortality. Statins, as widely used antilipidemic agents, work through their anti-inflammatory action and can alleviate the symptoms of COVID-19 infection.
In a retrospective study of 3133 patients with COVID-19 treated at two university hospitals in Wuhan, China from 26/1/2020 to 26/3/2020, in-hospital mortality was studied between patients receiving statin and those not receiving it. The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Kimon Stamatelopoulos, Alexandros Briasoulis, and Thanos Dimopoulos (Rector of EKPA) summarize the relevant publication in Nature.
The mean age of patients was 62 years, 49.8% were women, and 404 (12.9%) patients received statin. Compared to those who did not receive statins, these 404 patients were older, more likely to have comorbidities (coronary heart disease, diabetes, dyslipidemia, hypertension, heart failure, and atrial fibrillation), but had lower rates of IL-2 (inflammation ) and lower values ​​of δ-dimers 7 days after introduction. The statin group had a lower mortality risk (6.44% vs 10.88%). This difference was also observed in the subanalysis of patients with coronary heart disease.
Overall, an 87% lower risk of mortality was described for those taking statins, and this benefit was observed in those diagnosed with coronary heart disease and those who did not. Based on the results of this retrospective study, statin use was associated with a lower risk of in-hospital mortality in both patients with coronary heart disease and the rest. The retrospective nature of these data makes it necessary to confirm these findings in randomized prospective studies.
Follow Skai.gr on Google News
and be the first to know all the news
.
